Pharmacogenetic determinants of immediate and delayed reactions of Drug hypersensitivity

Current Pharmaceutical Design

Volumn 14, Issue 27, 2008, Pages 2770-2777

  Guéant, Jean Louis ^a,e   Gueant Rodriguez R M ^a   Gastin, I Aimore ^a   Cornejo Garcia J A ^a   Viola, M ^b   Barbaud, A ^c   Mertes, P M ^a   Blanca, M ^d   Romano, Antonio ^b,e  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b Unita di Allergologia   (Italy)

^c SERVICE DE DERMATOLOGIE   (France)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^e IRCCS Oasi Maria SS ^*  (France)

Author keywords

Lactams; Abacavir; Aspirin; Drug allergy; Drug hypersensitivity; Gene polymorphism; Pharmacogenetics; Sulfamethoxazole

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ALLOPURINOL; AMINOPENICILLIN; ARACHIDONIC ACID; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; COTRIMOXAZOLE; CYTOCHROME P450; CYTOCHROME P450 2C9; HLA A2 ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; HLA DR5 ANTIGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 3; INTERLEUKIN 4 RECEPTOR ALPHA; NONSTEROID ANTIINFLAMMATORY AGENT; SULFAMETHOXAZOLE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANGIONEUROTIC EDEMA; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; B LYMPHOCYTE; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DRESS SYNDROME; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; ETHNIC DIFFERENCE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOME ANALYSIS; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOGENETICS; IMMUNOPATHOLOGY; LYMPHOCYTE FUNCTION; MACULOPAPULAR RASH; PERIORBITAL EDEMA; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK REDUCTION; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TH2 CELL; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

ANIMALS; DRUG HYPERSENSITIVITY; HUMANS; HYPERSENSITIVITY, DELAYED; HYPERSENSITIVITY, IMMEDIATE; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 59649100974     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786369795     Document Type: Review

References (77)

1. World Health Organization. International drug monitoring: The role of national centres. World Health Organ Tech Rep Ser 1972; 498: 1-25.
2. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davis DM Ed. Textbook of adverse drug reactions. Oxford University Press: Oxford 1977; 10.
3. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-6.
4. Gomes E, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opinion Allergy Clin Immunol 2005; 5: 309-16.
5. Romano A, Demoly P. Recent advances in the diagnosis of drug allergy. Curr Opin Allergy Clin Immunol 2007; 7: 299-303.
6. Gatanaga H, Honda H, Oka S. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics 2008; 9: 207-14.
7. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139: 683-93.
8. Nelson MR, Bacanu SA, Mosteller M, Li L, Bowman CE, Roses AD, et al. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J 2008. [Epub ahead of print]
9. Gaspard I, Kerdine S, Pallardy M, Lebrec H. Quantitation of cytokine mRNA expression as an endpoint for prediction and diagnosis of xenobiotic-induced hypersensitivity reactions. Methods 1999; 19: 64-70.
10. Vandenbulcke L, Bachert C, Van Cauwenberge P, Claeys S. The innate immune system and its role in allergic disorders. Int Arch Allergy Immunol 2006; 139: 159-65.
11. Pieters R, Ezendam J, Nierkens S. Chemical-specific properties co-determine the type of adverse immune response. Autoimmun Rev 2003; 2: 25-9.
12. Guéant JL, Guéant-Rodriguez RM, Viola M, Valluzzi RL, Romano A. IgE-mediated hypersensitivity to cephalosporins. Curr Pharm Des 2006; 12: 3335-45.
13. Kinet JP. The high-affinity IgE receptor (Fc..RI): From physiology to pathology. Annu Rev Immunol 1999; 17: 931-72.
14. Qiao HL, Yang J, Zhang YW. Relationships between specific serum IgE, cytokines and polymorphisms in the IL-4, IL-4Ralpha in patients with penicillins allergy. Allergy 2005; 60: 1053-9.
15. Romano A, De Santis A, Romito A, Di Fonso M, Venuti A, Gasbarrini GB, et al. Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. Ann Allergy Asthma Immunol 1998; 80: 433-7.
16. Qiao HL, Yang J, Zhang YW. Specific serum IgE levels and FcepsilonRIbeta genetic polymorphism in patients with penicillins allergy. Allergy 2004; 59: 1326-32.
17. Punnonen J, Yssel H, de Vries JE. The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4+ or CD8+ T cells. J Allergy Clin Immunol 1997; 100: 792-801.
18. de Waal Malefyt R, Abrams JS, Zurawski SM, Lecron JC, Mohan- Peterson S, Sanjanwala B, et al. Differential regulation of IL-13 and IL-4 production by human CD8+ and CD4+ Th0, Th1 and Th2 T cell clones and EBV-transformed B cells. Int Immunol 1995; 7: 1405-16.
19. Aman MJ, Tayebi N, Obiri NI, Puri RK, Modi WS, Leonard WJ. cDNA cloning and characterization of the human interleukin 13 receptor alpha chain. J Biol Chem 1996; 271: 29265-70.
20. Gauchat JF, Schlagenhauf E, Feng NP, Moser R, Yamage M, Jeannin P, et al. A novel 4-kb interleukin-13 receptor alpha mRNA expressed in human B, T, and endothelial cells encoding an alternate type-II interleukin-4/interleukin-13 receptor. Eur J Immunol 1997; 27: 971-8
21. Yang J, Qiao HL, Dong ZM. Polymorphisms of IL-13 and IL-4-IL- 13-SNPs in patients with penicillin allergies. Eur J Clin Pharmacol 2005; 61: 803-9.
22. Guglielmi L, Fontaine C, Gougat C, Avinens O, Eliaou JF, Guglielmi P, et al. IL-10 promoter and IL4-Ralpha gene SNPs are associated with immediate beta-lactam allergy in atopic women. Allergy 2006; 61: 921-7.
23. Guéant-Rodriguez RM, Romano A, Béri-Dexheimer M, Viola M, Gaeta F, Guéant JL. Gene-gene interactions of IL13 and IL4RA variants in immediate allergic reactions to betalactam antibiotics. Pharmacogenet Genomics 2006; 16: 713-9.
24. Graves PE, Kabesch M, Halonen M, Holberg CJ, Baldini M, Fritzsch C, et al. A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children. J Allergy Clin Immunol 2000; 105: 506-13.
25. Heinzmann A, Mao XQ, Akaiwa M, Kreomer RT, Gao PS, Ohshima K, et al. Genetic variants of IL-13 signalling and human asthma and atopy. Hum Mol Genet 2000; 9: 549-59.
26. Liu X, Beaty TH, Deindl P, Huang SK, Lau S, Sommerfeld C, et al. Associations between total serum IgE levels and the 6 potentially functional variants within the genes IL4, IL13, and IL4RA in German children: The German Multicenter Atopy Study. J Allergy Clin Immunol 2003; 112: 382-38.
27. Zurawski SM, Vega F Jr, Huyghe B, Zurawski G. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J 1993; 12: 2663-70.
28. Howard TD, Koppelman GH, Xu J, Zheng SL, Postma DS, Meyers DA, et al. Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. Am J Hum Genet 2002; 70: 230-6.
29. Guéant-Rodriguez RM, Guéant JL, Viola M, Tramoy D, Gaeta F, Romano A. Association of tumor necrosis factor-alpha -308G>A polymorphism with IgE-mediated allergy to betalactams in an Italian population. Pharmacogenomics J 2008; 8: 162-8.
30. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. A marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.
31. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134-9.
32. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99-107.
33. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16: 297-306.
34. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006; 7: 813-8.
35. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5: 203-11.
36. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85.
37. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47: 1969-79.
38. Yang CW, Hung SI, Juo CG, Lin YP, Fang WH, Lu IH, et al. HLA-B*1502-bound peptides: Implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2007; 120: 870-7.
39. Pirmohamed M, Lin K, Chadwick D, Park BK. TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 2001; 56: 890-6.
40. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16: 297-306.
41. Alfirevic A, Mills T, Harrington P, Pinel T, Sherwood J, Jawaid A, et al. Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet Genomics 2006; 16: 287-96.
42. Naisbitt DJ, Gordon SF, Pirmohamed M, Burkhart C, Cribb AE, Pichler WJ, et al. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br J Pharmacol 2001; 133: 295-305.
43. Cribb AE, Spielberg SP, Griffin GP. N4-hydroxylation of sulfamethoxazole by cytochrome p450 of the cytochrome p4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat liver microsomes. Drug Metab Dispos 1995; 23: 406-14.
44. Gill HJ, Tjia JF, Kitteringham NR, Pirmohamed M, Back DJ, Park BK. The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation. Pharmacogenetics 1999; 9: 43-53.
45. Lin D, Tucker MJ, Rieder MJ. Increased adverse reactions to antimicrobials and anticonvulsants in patients with HIV infection. Ann Pharmacother 2006; 40: 1594-601.
46. Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug-metabolism in patients with acquired immunodeficiency syndrome. Clin Pharm Ther 1993; 53: 529-35.
47. Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 2007; 7: 324-30.
48. Pirmohamed M, Alfirevic A, Vilar J, Stalford A, Wilkins EG, Sim E, et al. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics 2000; 10: 705-13.
49. Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23: 1603-14.
50. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32.
51. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121-2.
52. Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004; 101: 4180-5.
53. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5: 203-11.
54. Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005; 19: 979-81.
55. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43: 99-102.
56. Reeves I, Churchill D, Fisher M. Screening for HLA-B*5701 reduces the frequency of abacavir hypersensitivity. Antivir Ther 2006; 11: L11.
57. Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Adquir Immune Defic Syndr 2007; 45: 1-3.
58. Phillips E, Rauch A, Nolan D. Pharmacogenetics and clinical characteristics of patch test confirmed patients with abacavir hypersensitivity. Rev Antivir Ther 2006; 3: 57.
59. Phillips EJ, Sullivan JR, Knowles SR, Shear NH. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 2002; 16: 2223-5.
60. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-79.
61. Kim SH, Ye YM, Lee SK, Park HS. Genetic mechanism of aspirininduced urticaria/angioedema. Curr Opin Allergy Clin Immunol 2006; 6: 266-70
62. Kim SH, Park HS. Genetic markers for differentiating aspirin-hypersensitivity. Yonsei Med J 2006; 47: 15-21.
63. Simon RA. Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep 2004; 4: 17-24.
64. Kim SH, Choi JH, Lee KW, Kim SH, Shin ES, Oh HB, et al. The HLA-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin Exp Allergy 2005; 35: 339-44.
65. Blanca M, Perez E, Garcia JJ, Miranda A, Terrados S, Vega JM, et al. Angioedema and IgE antibodies to aspirin: A case report. Ann Allergy 1989; 62: 295-8.
66. Bae JS, Kim SH, Ye YM, Yoon HJ, Suh CH, Nahm DH, et al. Significant association of FcepsilonRIalpha promoter polymorphisms with aspirin-intolerant chronic urticaria. J Allergy Clin Immunol 2007; 119: 449-56.
67. Choi JH, Kim SH, Suh CH, Nahm DH, Park HS. Polymorphisms of high-affinity IgE receptor and histamine-related genes in patients with ASA-induced urticaria/angioedema. J Korean Med Sci 2005; 20: 367-72
68. Mastalerz L, Setkowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: Common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol 2004; 113: 771-5.
69. Mastalerz L, Setkowicz M, Sanak M, Rybarczyk H, Szczeklik A. Familial aggregation of aspirin-induced urticaria and leukotriene C synthase allelic variant. Br J Dermatol 2006; 154: 256-60.
70. Torres-Galvan MJ, Ortega N, Sanchez-Garcia F, Blanco C, Carrillo T, Quiralte J. LTC4-synthase A-444C polymorphism: Lack of association with NSAID-induced isolated periorbital angioedema in a Spanish population. Ann Allergy Asthma Immunol 2001; 7: 506-10.
71. Kim SH, Choi JH, Holloway JW, Suh CH, Nahm DH, Ha EH, et al. Leukotriene-related gene polymorphisms in patients with ASA-induced urticaria and ASA-intolerant asthma: Differing contributions of ALOX5 polymorphism in Korean population. J Korean Med Sci 2005; 20: 926-31.
72. Mathelier-Fusade P. Drug-induced urticaria. Clin Rev Allergy Immunol 2006; 30: 19-24.
73. Kim SH, Oh JM, Kim YS, Palmer LJ, Suh CH, Nahm DH, et al. Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males. Clin Exp Allergy 2006; 36: 433-9.
74. Choi JH, Park HS, Oh HB, Lee JH, Suh YJ, Park CS, et al. Leukotriene- related gene polymorphisms in ASA-intolerant asthma: An association with a haplotype of 5-lipoxygenase. Hum Genet 2004; 114: 337-44.
75. Altmann KH, Memmert K. Epothilones as lead structures for new anticancer drugs-pharmacology, fermentation, and structure-activity- relationships. Prog Drug Res 2008; 66: 275-334.
76. Bansal AT, Barnes MR. Genomics in drug discovery: The best things come to those who wait. Curr Opin Drug Discov Devel 2008; 11(3): 303-11.
77. Giovannetti A, Pierdominici M, Di Iorio A, Cianci R, Murdaca G, Puppo F, et al. Apoptosis in the homeostasis of the immune system and in human immune mediated diseases. Curr Pharm Des 2008; 14(3): 253-68.